Hey hoops, Sorry, I usually agree with you, but I have to

New Post Public Reply Private Reply Replies (3) Message Board
tc2000chartreader hoops #2388
265
Hey hoops,
Sorry, I usually agree with you, but I have to disagree this time. Joe mentioned in the last cc that they are looking for a shell company to reverse into and go public. They would have to buy that shell, do their due diligence that everything old on that shell is removed so it doesn't come back to bite us, and then look to move our shares into it. So the initial shares will be book entry at NuGenerex saying you are entitled to those shares when they complete all the above. So I don't think anyone should expect to see shares in their brokerage account for NGIO.

As far as last time, the purchaser of the GNBT shares before the exdiv date (which was the day after the payable date due to greater than 25% distribution), were entitled to the shares from the dividend. SInce the clearing is trade date + 2 days, the Wednesday 12/5 date made sense and that is when my shares showed up at TD Ameritrade.

And I would imagine we will get a reminder PR about the cc call tomorrow at 11AM. That may come tomorrow morning, or maybe today.

We are creating our OWN SPECULATION. Some here post that they expect a PR today, and when one doesn't come, several decide NuGenerex is letting us down. That is of our own creation.
Quote:
I count at least six PR's that reference the spin off of NGIO. People bought shares in Generex because they wanted to participate in the spin-off. There was the potential for a secondary offering, IPO, or total buyout. The ex-div date was pushed back, halting all momentum, but we wait patiently for today.

Today comes. No PR. No explanation. No evidence of the shares or their value. I'm sure there is more to the story than this, but the initial impression is that something is wrong. Remember how we couldn't get the GNBT div shares until Dec. 5th instead of Dec. 3rd? This is the MO of OlGenerex, not NuGenerex.

Volume is low today, so it looks like Generex gets a mulligan. However, a well thought out PR is warranted so that we know what to expect. I don't think that's asking too much. Without fact you get speculation and we've had our share of that.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

FutureVault's AI Agents: Transforming Financial Workflows

Updated Category News Views 4

Revolutionizing Financial Operations: FutureVault's AI Approach In the dizzying whirlwind of financial services, the launch of FutureVault AI Agents is a game-changer for document management. This isn't some half-baked tool; it's a full-fledged overhaul of how compliance and operations should tick in the modern age. We've all seen it—a paper trail tangled across systems...

Continue Reading
Machine Grabs Prime Dallas Property Amid Apartment Boom

Updated Category News Views 7

Dallas' Hot Market and Machine's Bold Move Well, well, looks like Machine Investment Group's been busy flexing its real estate muscles, bagging a 490-unit gem in North Dallas—your typical, no-frills off-market grab. We’re talking 75 West, nestled in a juicy infill spot, and it’s catching eyes like gold dust in a pan. You don't need me to tell you North Dallas ain't...

Continue Reading
Leapora's Taskeen: Redefining Task Accountability

Updated Category News Views 5

AI's Impact on Workplace Task Management In today’s whirlwind of AI-generated output, transparency is not just a luxury; it’s a necessity. AI systems churn out work that can appear polished but often lacks substance. This doesn't just create headaches; it triggers a ticking bomb in the regulatory department. According to a 2025 survey from Stanford and BetterUp Labs,...

Continue Reading
Sean Trahan Joins Citrin Cooperman: New Tax Lead

Updated Category News Views 8

Citrin Cooperman's Strategic Tax Move If there's one phrase that can spark a debate at a financial water cooler, it's 'transfer pricing.' Today, Citrin Cooperman is throwing its hat further into that ring with the appointment of Sean Trahan as head of their new Transfer Pricing and Value Chain Optimization Practice. This isn't just another reshuffling of office...

Continue Reading
Compass Unveiled: Power Revolution in Private Equity

Updated Category News Views 8

AI-Driven Insights: Revolutionizing Private Equity Strategies Now this is some spicy news from Huntington Beach! Collective just pulled back the curtain on Compass, their AI-fueled platform that's set to shake up how financial advisors tackle private company equity. If you're an advisor who's sick of staring at nebulous balance sheets filled with unquantifiable private...

Continue Reading
Anecdotes by Artists Brings Raw Scent Stories to Sephora

Updated Category News Views 3

When Maesa pulls back the curtain, they don't just crack it open—they fling it aside with flair. That's precisely what they're doing with their latest venture, Anecdotes by Artists, a fragrance brand that's taking its first bow exclusively at Sephora. It's not your average perfume launch; it's about the stories behind the scents and the artists who craft them. Unveiling...

Continue Reading
Succession Planning in Turmoil: Only 42% Ready

Updated Category News Views 5

Diving into the Succession Crisis in Finance Succession planning in the financial advisory space is like retirement planning for the rest of us—everyone knows it's crucial, yet too many put it off. Despite the looming retirement wave and desperate interest from the younger cohort, a staggering 42% of financial advisors are still without a documented succession game...

Continue Reading
Davos Healthcare Aims to Revolutionize Hospital Ratings

Updated Category News Views 7

Throw away those dusty, old reputation surveys—Davos Healthcare just turned the spotlight onto cold, hard data with its new global hospital evaluation platform. Why Davos Healthcare’s Initiative Matters At the C3 US NYC Davos of Healthcare™ Summit, an event that’s rooted itself alongside the United Nations General Assembly, Davos Healthcare unveiled a...

Continue Reading
FJBio Boosts Antibody Discovery with Sapio AI

Updated Category News Views 5

In the sprawling world of antibody discovery, where every scrap of data can make or break the next big breakthrough, FairJourney Bio (FJBio) is pulling out all the stops. They've teamed up with Sapio Sciences to ditch the paperwork nightmares and usher in a new era of AI-driven efficiency. With operations stretching from Porto to Cambridge to sunny San Diego, they’re...

Continue Reading
The Chemical Industry and EPA: A Broken System?

Updated Category News Views 6

Decades of an Unchecked Revolving Door The Environmental Protection Agency (EPA) and chemical manufacturers—a dance that’s been going on for what seems like forever. But not in the way you might hope. We're talking about a revolving door where execs and lobbyists waltz into regulatory chairs while regulators slide into cushy industry gigs. Wisner Baum LLP, a stickler...

Continue Reading

Top 5 Most Recently Viewed Articles

Sharecare Inc. Achieves New Heights with Stock Performance

Updated Category News Views 89

Sharecare Inc. Hits New Stock High Sharecare Inc. (NASDAQ: SHCR) is making waves as its stock reaches a notable 52-week high of $1.41. This milestone is more than just a statistic; it signifies a significant turnaround for this pioneering digital health company. The stock has appreciated by an impressive 44.86% over the past year, reflecting the company's resilience and...

Continue Reading
Exploring the Exciting Growth of AI in Precision Medicine

Updated Category News Views 150

The Rise of AI in Precision Medicine Artificial Intelligence (AI) is not just a trend; it is a revolution in precision medicine. As healthcare evolves, the need for targeted therapies to address chronic and genetic disorders has become paramount. The landscape of medicine is changing, with innovations in personalized treatments ushered in by AI technologies that analyze...

Continue Reading
Tacotarian: A Pioneer in Plant-Based Dining Excellence

Updated Category News Views 133

Tacotarian's Recognition in the Fast Casual Industry The only plant-based restaurant recognized, Tacotarian is now expanding nationwide through franchising. Recently, Tacotarian has been honored by being named to Fast Casual's Top 100 Movers & Shakers of 2024. This prestigious acknowledgment celebrates brands that stand out for their innovation and impact within the...

Continue Reading
How Technology Is Reducing Operational Risk Across the Financial Services Industry

Updated Category Business Views 76

Operational risk is getting more expensive. According to research cited by TechRadar Pro, in 2024, the average cost of a data breach in the financial industry reached a whopping $6.08 million - which is significantly higher than the global cross-industry average.  For financial institutions, one system failure or compliance lapse can erase years of operational gains....

Continue Reading
RegScale Sees Impressive Growth: Understanding Its Journey

Updated Category News Views 710

RegScale's Unprecedented Growth and Innovations In recent times, RegScale has showcased remarkable progress, tripling its Annual Recurring Revenue (ARR) and expanding its influence in both the federal and commercial sectors. The company's Continuous Controls Monitoring (CCM) platform, tailored for Chief Information Security Officers (CISOs), has become increasingly...

Continue Reading